# OnCo record peripheral-t-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/peripheral-t-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "peripheral-t-cell-lymphoma" ;
  schema:name "Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)"@en ;
  schema:alternateName "PTCL"@en, "CTCL"@en, "Mycosis fungoides"@en, "Anaplastic large-cell lymphoma"@en, "Mature T-cell and NK-cell neoplasms"@en, "T-cell lymphoma"@en, "NK-cell lymphoma"@en, "Peripheral T-cell lymphoma, not otherwise specified"@en, "PTCL-NOS"@en ;
  schema:description "Peripheral T-cell lymphomas are lymphomas of T cells rather than B cells. They are rarer, more varied and, apart from a few subtypes, harder to treat than B-cell lymphomas; several new drugs help only defined subtypes."@en ;
  schema:url <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Peripheral_T-cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7168693> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483>, <https://doi.org/10.1016/S0140-6736(18)32984-2>, <https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/clinical-trials-lymphoma-trialslink/taking-part-clinical>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/stem-cell-transplants/self-autologous-stem-cell>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma>, <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/biomarkers/rhoa-g17v/>, <https://onco.cc/biomarkers/ig-tcr-clonality/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/>, <https://onco.cc/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/clonality-testing/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/ccr4/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/cd52/>, <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/stat3/>, <https://onco.cc/targets/stat5/>, <https://onco.cc/targets/jak1/>, <https://onco.cc/targets/jak3/>, <https://onco.cc/targets/rhoa/>, <https://onco.cc/targets/tet2/>, <https://onco.cc/targets/dnmt3a/>, <https://onco.cc/targets/vav1/>, <https://onco.cc/targets/irf4/>, <https://onco.cc/targets/plcg1/>, <https://onco.cc/targets/card11/>, <https://onco.cc/targets/fyn/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/alemtuzumab/>, <https://onco.cc/drugs/interferon-alfa/> ;
  onco:companies <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/bioinvent-international/>, <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/immuneoncia-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/inflammation-nfkb/> ;
  onco:terms <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-failed-and-negative/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/>, <https://onco.cc/terms/lymphoma-living-returning-to-work/>, <https://onco.cc/terms/lymphoma-bio-htlv1/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/>, <https://onco.cc/terms/lymphoma-bio-ebv-latency/>, <https://onco.cc/terms/lymphoma-pit-score/>, <https://onco.cc/terms/lymphoma-htlv-1/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/> ;
  onco:trials <https://onco.cc/trials/nct06561048/>, <https://onco.cc/trials/nct06776952/>, <https://onco.cc/trials/nct06072131/>, <https://onco.cc/trials/nct04668690/>, <https://onco.cc/trials/alcanza/>, <https://onco.cc/trials/echelon-2/>, <https://onco.cc/trials/jcog9801/>, <https://onco.cc/trials/smile-enktl/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-horwitz-lancet/> ;
  onco:pipeline <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/soquelitinib/>, <https://onco.cc/drugs/azd3470/>, <https://onco.cc/drugs/dr-01/> ;
  onco:standardOfCare <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/mogamulizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/lymphoma-type/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/trials/echelon-2/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/key-papers/paper-horwitz-lancet/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-failed-and-negative/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/pralatrexate/>, <https://onco.cc/drugs/belinostat/>, <https://onco.cc/drugs/romidepsin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/alemtuzumab/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/> .